NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells

Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a Food and Drug Administration–approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-sta...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Biol Chem
Main Authors: Farah, Elia, Li, Chaohao, Cheng, Lijun, Kong, Yifan, Lanman, Nadia A., Pascuzzi, Pete, Lorenz, Gabrielle Renee, Zhang, Yanquan, Ahmad, Nihal, Li, Lang, Ratliff, Tim, Liu, Xiaoqi
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Biochemistry and Molecular Biology 2019
נושאים:
Cell Biology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6544854/
https://ncbi.nlm.nih.gov/pubmed/30940724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA118.006983
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים